S 2474

Drug Profile

S 2474

Latest Information Update: 15 Jul 2002

Price : $50

At a glance

  • Originator Shionogi
  • Class Analgesics; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories
  • Mechanism of Action Antioxidants; Cyclo-oxygenase 2 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 15 Jul 2002 Discontinued - Phase-I for Rheumatoid arthritis in Japan (PO)
  • 15 Jul 2002 Discontinued - Phase-II for Rheumatoid arthritis in Europe (PO)
  • 29 May 2001 S 2474 is available for licensing (http://www.shionogi.co.jp)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top